<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03836768</url>
  </required_header>
  <id_info>
    <org_study_id>DTRM_DTRMWXHS-12_004</org_study_id>
    <nct_id>NCT03836768</nct_id>
  </id_info>
  <brief_title>BTK Inhibitor DTRMWXHS-12 in Mantle Cell Lymphoma</brief_title>
  <official_title>A Phase Ib Study of BTK Inhibitor DTRMWXHS-12 in Patients With Relapsed/Refractory Mantle Cell Lymphoma (MCL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhejiang DTRM Biopharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zhejiang DTRM Biopharma</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Primary Objective is to evaluate the safety and tolerability of the DTRMWXHS-12 capsule&#xD;
      in patients with relapsed/refractory MCL and recommend the dose and dosing method (RP2D) used&#xD;
      in phase II study.&#xD;
&#xD;
      The Secondary Objective is to evaluate the pharmacokinetics (PK) of multiple dose oral&#xD;
      administration of DTRMWXHS-12 capsule in patients with relapsed/refractory MCL.&#xD;
&#xD;
      The Exploratory Objective is to preliminarily evaluate the efficacy of DTRMWXHS-12 capsule in&#xD;
      patients with relapsed/refractory MCL.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 11, 2019</start_date>
  <completion_date type="Anticipated">November 2022</completion_date>
  <primary_completion_date type="Anticipated">November 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety: Incidence and severity of (serious) adverse events n each patient according to the NCI-CTCAE4.03 grading</measure>
    <time_frame>Starting from date of first dose up to 35 days after last dose</time_frame>
    <description>To monitor AEs and SAEs in each patient according to the NCI-CTCAE4.03 grading criteria by evaluating changes in physical examination, laboratory tests, and 12-lead ECG during the whole study</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>concentration of drug in plasma</measure>
    <time_frame>From date of first dose to day 56</time_frame>
    <description>concentration of drug in plasma</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Overall response rate (ORR)</measure>
    <time_frame>From date of first dose to date of disease progression, an average of 6 months</time_frame>
    <description>Percentage of patients with PR, CR</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Mantle Cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>Experimental Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DTRMWXHS-12, oral capsule, daily, 28 days as a cycle</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DTRMWXHS-12</intervention_name>
    <description>DTRMWXHS-12 capsules: 150 mg, 300 mg</description>
    <arm_group_label>Experimental Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          1. 18-75 Years old (include 18 and 75), gender is not limited.&#xD;
&#xD;
          2. Measurable lesions by computed tomography (CT)/magnetic resonance imaging (MRI). A&#xD;
             measurable lesion is defined as follows: at least the longest diameter of one lymph&#xD;
             node &gt;1.5cm and clearly measurable in two vertical directions, or at least the longest&#xD;
             diameter of one extranodal lesion &gt;1cm (e.g., liver nodule); If only spleen or&#xD;
             gastrointestinal mucosa is involved, corresponding examinations and evaluations will&#xD;
             be conducted in the investigator's opinion.&#xD;
&#xD;
          3. The diagnosis report must contain morphology and evidence of positive cyclin D1 by&#xD;
             immunohistochemistry or evidence of t (11; 14). The above results are tested by&#xD;
             immunohistochemistry, cytogenetics or Fluorescent in situ hybridization (FISH). After&#xD;
             enrollment, tumor tissue (FFPE) blocks or sections must be sent to the central&#xD;
             laboratory for confirmation of MCL.&#xD;
&#xD;
          4. The laboratory parameters are as follows:&#xD;
&#xD;
               1. Hematology: Neutrophils ≥ 1.0×10^9/L without growth factor or blood transfusion,&#xD;
                  platelets ≥ 75×10^9L (≥50×10^9/L if bone marrow is involved), and hemoglobins &gt;&#xD;
                  9g/dL within 7 days before enrollment into the study.&#xD;
&#xD;
               2. Liver: Aspartate aminotransferase (AST)/serum glutamic oxaloacetic transaminase&#xD;
                  (SGOT) and alanine aminotransferase (ALT)/serum glutamic pyruvic transaminase&#xD;
                  (SGPT) ≤ 2.5×ULN; total bilirubin ≤ 2×ULN (&lt; 3×ULN when diagnosed as Gilbert's&#xD;
                  syndrome).&#xD;
&#xD;
               3. Kidney: Creatinine clearance≥30 ml/min (Evaluated by estimated glomerular&#xD;
                  filtration rate [eGFR] according to the Cockcroft-Gault Equation or the&#xD;
                  calculation equation of each site); Cockcroft-Gault equation= Female:&#xD;
                  (140-age)×weight(kg)×0.85/(72×serum creatinine (mg/dL)) Male: (140-age)×body&#xD;
                  weight(kg)/(72×serum creatinine(mg/dL))&#xD;
&#xD;
               4. international normalized ratio(INR) ≤ 1.5×ULN and activated partial&#xD;
                  thromboplastin time (APTT) ≤ 1.5×ULN, and for patients with acquired hemophilia&#xD;
                  or those treated with clotting factor inhibitors or vitamin K antagonists, the&#xD;
                  enrollment will be determined after discussion with the investigator.&#xD;
&#xD;
          5. ECOG performance status score 0-2.&#xD;
&#xD;
          6. Life expectancy &gt; 3 months.&#xD;
&#xD;
          7. There must be documentations on relapsed or refractory lymphoma or disease progression&#xD;
             after systemic therapy and at least one but less than five therapies for mantle cell&#xD;
             lymphoma were administrated previously (1 ≤ number of previous therapies &lt; 5).&#xD;
&#xD;
          8. No response with the last therapy (SD or PD during the treatment), or PD after the&#xD;
             therapy.&#xD;
&#xD;
          9. Patients with disease recurrence at least 3 months after autologous hematopoietic stem&#xD;
             cell transplantation can be enrolled into the study, if there isn't any relevant&#xD;
             active infection.&#xD;
&#xD;
         10. Females of child-bearing potential must agree to use highly effective contraception&#xD;
             methods during the study and at least 180 days after the last dose of the&#xD;
             investigational drug. Highly effective contraception methods include abstinence,&#xD;
             hysterectomy, bilateral ovariectomy without menstruation for six consecutive months,&#xD;
             intrauterine contraception systems, hormonal contraception such as injectable&#xD;
             contraceptives and oral contraceptives. Males must be sterilized via either vasectomy,&#xD;
             or use barrier methods, while their female partners should take the effective&#xD;
             contraception methods mentioned above.&#xD;
&#xD;
         11. Patients are voluntary to sign the informed consent form and can understand and comply&#xD;
             with all study requirements.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          1. Patients suffering from or previously suffering from CNS lymphoma.&#xD;
&#xD;
          2. Patients received other BTK inhibitors prior to enrollment. Patients who received&#xD;
             steroid anti-tumor therapy (a dose equivalent to&gt;20mg/day of prednisone) within 7&#xD;
             days, or received chemotherapy, targeted therapy, or radiotherapy within 4 weeks, or&#xD;
             received anti-tumor Chinese medicinal herbs or antibody therapy within 4 weeks, prior&#xD;
             to first administration of DTRMWXHS-12 capsule.&#xD;
&#xD;
          3. Patients received major surgery in the past 4 weeks before screening (determined by&#xD;
             the investigator according to the patient's condition).&#xD;
&#xD;
          4. Patients with active bleeding or combination with anticoagulant therapy within 3-6&#xD;
             months.&#xD;
&#xD;
          5. Patients had undergone chemotherapy before and in whom the toxicity has not resolved&#xD;
             (the toxicity has not resolved to ≤ grade 1 as per National Cancer Institute's Common&#xD;
             Terminology Criteria for Adverse Events (CTCAE) Version 4.03, except for hair loss,&#xD;
             absolute neutrophil count (ANC) and platelets). For neutrophils and platelets, please&#xD;
             refer to the criterion 4 [Neutrophils] and [Platelets] in the inclusion criteria.&#xD;
&#xD;
          6. Patients with a history of other active malignant diseases within 2 years prior to&#xD;
             enrollment into the study, excluding the following: (1) adequately treated cervical&#xD;
             carcinoma in situ; (2) local skin basal cell carcinoma or squamous cell carcinoma; (3)&#xD;
             malignant diseases that has been controlled and completely locally treated (by surgery&#xD;
             or other means)&#xD;
&#xD;
          7. Patients suffering from active cardiovascular diseases with clinical significance,&#xD;
             such as uncontrolled arrhythmia, congestive heart failure, Grade 3 or 4 heart disease&#xD;
             according to New York Heart Association (NYHA) Functional Classification, or those&#xD;
             with history of myocardial infarction within 6 months before screening.&#xD;
&#xD;
          8. QTcF&gt;450 msecs or other significant ECG abnormalities, including second-degree&#xD;
             atrioventricular block type Ⅱ, third-degree atrioventricular block.&#xD;
&#xD;
          9. Patients who can't swallow capsules or with diseases significantly affect the&#xD;
             gastrointestinal function, such as malabsorption syndrome, gastric or intestinal&#xD;
             resection, symptomatic inflammatory bowel disease, or partial or complete intestinal&#xD;
             obstruction.&#xD;
&#xD;
         10. Uncontrolled systemic infections or infections requiring to be treated with&#xD;
             intravenous antibacterial agents.&#xD;
&#xD;
         11. Patients who previously received allogeneic stem cell transplantation.&#xD;
&#xD;
         12. Patients known to have been infected with human immunodeficiency virus (HIV) or active&#xD;
             hepatitis B or hepatitis C virus (polymerase chain reaction [PCR] or reverse&#xD;
             transcription- polymerase chain reaction (RT-PCR) shows positive results).&#xD;
&#xD;
         13. Hepatitis B test includes HBsAg, HBcAb and HBsAb. If the patient is HBsAg-negative but&#xD;
             HBcAb-positive (regardless of HBsAb), the PCR technology will be used to detect&#xD;
             hepatitis B virus (HBV) DNA, and the acceptable upper limit of normal in the table&#xD;
             below is 1000 IU/mL. Considering different PCR kits may be used by different sites,&#xD;
             the acceptable upper limit of normal for HBV DNA should be the normal value in the&#xD;
             site. Hepatitis C test includes hepatitis C virus (HCV) antibody test, and if the HCV&#xD;
             antibody is positive, the RT-PCR technology will be used to detect HCV RNA.&#xD;
&#xD;
         14. Pregnant or lactating women.&#xD;
&#xD;
         15. Any life-threatening disease, medical condition, or organ system dysfunction that, in&#xD;
             the investigator's opinion, may affect subject safety or lead to study risks.&#xD;
&#xD;
         16. Patients with poor compliance.&#xD;
&#xD;
         17. Patients who receive treatment with a potent CYP3A (cytochrome P450, family 3,&#xD;
             subfamily A) inhibitor or a potent CYP3A inducer within 7 days prior to enrollment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wei He, Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Zhejiang DTRM Biopharma</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Peking University Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>January 30, 2019</study_first_submitted>
  <study_first_submitted_qc>February 7, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 11, 2019</study_first_posted>
  <last_update_submitted>August 18, 2021</last_update_submitted>
  <last_update_submitted_qc>August 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Mantle-Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

